Barry Nassberg, WFS’ Group Chief Commercial Officer, commented: “Since the start of the COVID pandemic, WFS has been at the forefront of the global response, ensuring vital supplies of Personal Protective Equipment and other medical supplies arriving at airports for hospitals and medical centres around the world have been handled quickly and securely to help save the lives of patients recovering from the virus, and support front-line medical personnel. We are extremely proud to be playing a key role in the international response to COVID and the next big stage of this will be the rapid and safe distribution of vaccines once they are approved. WFS’ significant investment in dedicated facilities and training for pharma shipments means we are uniquely placed to meet the requirements of governments, the pharma industry and our customers. They can be assured of our robust support.”
Across its network of pharma facilities, WFS’ capabilities include:
• Dedicated facilities in the heart of airport cargo zones to expedite handling of imports and exports
• Ability to manage shipments requiring both +2°C to +8°C and +15°C to +25°C temperature environments, and -20°C in some of our stations.
• Real-time temperature monitoring and temperature excursion alarms
• Full track and trace capabilities
• Active temperature-controlled container handling
• Temperature-controlled trucks, trailers and dollies
• Landside and airside acceptance
As well as facilities dedicated to the safe storage, handling and transportation of pharma and medical devices, WFS has dedicated teams of specialists assigned to each location. They have either completed IATA CEIV training or the special Pharma Module covering handling, audits, quality and risk management for temperature-controlled cargoes developed by the WFS Academy, accredited by IATA as one of the world’s top 10 aviation training providers.
